FibroGen (NASDAQ:FGEN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened

FibroGen, Inc. (NASDAQ:FGEN)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.45 and traded as high as $0.61. FibroGen shares last traded at $0.57, with a volume of 1,271,728 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. Finally, StockNews.com initiated coverage on shares of FibroGen in a report on Wednesday, January 1st. They issued a “hold” rating for the company.

FibroGen Trading Down 4.9 %

The stock has a market cap of $50.79 million, a P/E ratio of -0.41 and a beta of 0.75. The stock’s fifty day moving average price is $0.46 and its 200 day moving average price is $0.49.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the company earned ($0.52) earnings per share. On average, analysts anticipate that FibroGen, Inc. will post -0.8 earnings per share for the current year.

Institutional Trading of FibroGen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 DIFC Ltd increased its stake in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA bought a new position in shares of FibroGen during the 2nd quarter worth approximately $48,000. Franklin Street Advisors Inc. NC lifted its holdings in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen in the second quarter valued at about $130,000. Finally, Sei Investments Co. increased its stake in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.